Wolverine Asset Management LLC Cerevel Therapeutics Holdings, Inc. Put Options Transaction History

Wolverine Asset Management LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 13, 2024	SELL	$40.88 - $43.27 $10.1 Million - $10.7 Million	-246,700 Reduced 89.48%	29,000 $1.23 Million
Q3 2023 Nov 13, 2023	BUY	$20.26 - $31.91 $666,554 - $1.05 Million	32,900 Added 13.55%	275,700 $6.02 Million
Q2 2023 Aug 07, 2023	BUY	$23.9 - $35.38 $64,529 - $95,526	2,700 Added 1.12%	242,800 $7.72 Million
Q1 2023 May 08, 2023	BUY	$22.82 - $35.32 $1.02 Million - $1.58 Million	44,600 Added 22.81%	240,100 $5.86 Million
Q4 2022 Feb 01, 2023	BUY	$25.35 - $31.96 $1.52 Million - $1.91 Million	59,900 Added 44.17%	195,500 $6.17 Million
Q3 2022 Nov 10, 2022	BUY	$25.5 - $41.42 $3.46 Million - $5.62 Million	135,600 New	135,600 $3.83 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.